KRAFTON Showcases AI Model ‘CPC’ Built with NVIDIA ACE at CES 2025
KRAFTON (CEO Changhan ‘CH’ Kim) set a new milestone for the global gaming industry with the introduction of ‘CPC’ (Co-Playable Character), an NPC (Non-Player Character) brought to life with generative AI, in collaboration with NVIDIA, at the world’s largest IT exhibition CES 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108628507/en/
Kangwook Lee, Head of the Deep Learning Division at KRAFTON (Photo: KRAFTON)
On January 8, KRAFTON joined NVIDIA at the Fontainebleau Hotel in Las Vegas. KRAFTON showcased an innovative AI experience built with NVIDIA ACE technologies, presenting a bold vision for the future of gaming.
Kangwook Lee, Head of the Deep Learning Division at KRAFTON, demonstrated CPC, describing it as “a groundbreaking character concept enabled by an on-device SLM (Small Language Model) for gaming, built with NVIDIA ACE.” He explained that unlike traditional NPCs, a CPC is capable of dynamic interactions with players, including real-time conversations, strategic cooperation, and flexible responses tailored to in-game scenarios.
Lee highlighted KRAFTON’s commitment to expanding CPC technology across its gaming portfolio, including the PUBG IP Franchise and inZOI. He stated, “We will continue to innovate user experiences by integrating CPC into our games and aim to establish it as a benchmark for the gaming industry.” He added, “Our collaboration with NVIDIA is a testament to the transformative potential of AI in gaming, and we plan to work closely together to push the boundaries of what is possible.”
KRAFTON also presented video demonstrations of CPC technology in action within its games. In the case of PUBG IP Franchise, the video revealed ‘PUBG Ally,’ a CPC capable of engaging in casual conversations, adapting strategies, and refining gameplay to align with user dynamics.
For inZOI, the demonstration highlighted ‘Smart Zoi,’ a CPC with distinct personality traits and emotional depth, offering highly immersive simulation experiences through lifelike interactions with players.
During CES 2025, KRAFTON set up demos with NVIDIA where attendees could experience CPC-integrated gameplay and its innovation firsthand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108628507/en/
Contacts
KRAFTON
Christine Chung
christine.chung@krafton.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarginEdge Selects BlueSnap as North American Subscription Payments Partner9.1.2025 15:00:00 CET | Press Release
BlueSnap, a global payment orchestration platform for leading B2B and B2C businesses, today announced its selection by MarginEdge, a provider of restaurant management solutions, as its North American client billing partner. MarginEdge helps restaurant owners and managers get out of the back office and back onto the restaurant floor by automating their operations. Its comprehensive platform of restaurant management solutions includes inventory management, access to real-time food costs, and integrated payments for operators to easily pay their bills. MarginEdge selected BlueSnap’s next-generation solution to streamline the collection of client billing across North America – an important infrastructure update as the company continues to grow its customer base outside of the US. “BlueSnap quickly demonstrated an understanding of the challenges companies like us face when navigating cross-border client billing complexities,” said Bo Davis, CEO and Co-Founder at MarginEdge. “Thanks to BlueS
EV Group successfully finalises an investment in Cornelius Group plc through a minority equity stake.9.1.2025 14:33:00 CET | Press Release
EV Group, a leading specialty chemicals and food ingredients distributor and manufacturer, and Cornelius Group (Cornelius), an international manufacturer and distributor of specialty additives and ingredients to the life sciences and performance chemicals markets, announce today that they have reached binding agreements for the acquisition by EV of a minority stake in Cornelius. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109291745/en/ Photographed (Left to Right): Darren Spiby, Joint CEO, Cornelius Group plc; Phillip Gibbons, Joint CEO, Cornelius Group plc; Dr Neville Prior, Group Chairman, Cornelius Group plc; Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Cristina Colombo, Chief Financial Officer, EV Group; Gabriele Bonomi, Chief Executive Officer, EV Group. (Photo: Business Wire) Under the terms of the transaction, EV Group will increase its stake in Cornelius through additional equity acquis
Cirium Launches Industry-First GenAI Assistant for On-Time Performance9.1.2025 14:00:00 CET | Press Release
Cirium, the world’s most trusted source of aviation analytics, has unveiled the industry’s first generative AI assistant designed specifically for airline and airport on-time performance (OTP). OTP Awards AI is the first of Cirium’s generative AI assistants designed to supplement the analysis of Cirium’s 2024 On-Time Performance Review. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108288275/en/ Cirium's new On-Time Performance Awards AI assistant (Photo: Business Wire) The AI assistant empowers anyone connected to aviation to dig deeper into the top performer results, review the on-time performance scores, tracked flights and completion factor insights, and uncover performance trends with ease. With this tool, users can query and compare their metrics with industry leaders to identify performance gaps. “2025 will be a pivotal year for aviation as it seeks to enhance the use of analytics and automate workflows,” said Jer
Agendia, Inc. Provides Review of Successful 20249.1.2025 14:00:00 CET | Press Release
Agendia®, Inc. today provided a topline review of the company’s key milestone achievements in 2024. These updates include significant inroads in expanding market access, product innovation, commercial growth, advancements in research, as well as key partnerships and awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109282376/en/ Personalized biology-based insights (Graphic: Business Wire) “In the past year, Agendia has made great progress in advancing the field of precision oncology and genomic testing. We have seen success across multiple aspects of our business, including global expansion and clinical adoption of our proprietary assays, MammaPrint® and BluePrint®, advancement of our clinical milestones, expansion of our global market access, and formation of strong partnerships with professional and advocacy organizations,” said Mark R. Straley, Chief Executive Officer of Agendia. “Our mission of empowering patient
Areteia Therapeutics to Present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 20259.1.2025 13:27:00 CET | Press Release
Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event: J.P. Morgan Healthcare Conference Venue: The Westin St. Francis, San Francisco, CA Date: January 14, 2025 Time: 1:30 p.m. - Pacific Time Location: Golden Gate room (32nd Floor), The Westin St. Francis Presenter: Jorge Bartolome, Chief Executive Officer About Areteia Areteia is a clinical-stage biotechnology company engaged in the development of a potential first-in-class oral therapeutic remedy for diseases associated with elevated eosinophil levels with an initial focus on severe eosinophilic asthma. The Company has advanced its investiga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom